Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database
Vaccination against COVID-19 is the cornerstone of controlling and mitigating the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. While the Oxford-AstraZeneca vaccine has received much of t...
Guardado en:
Autores principales: | Mansour Tobaiqy, Katie MacLure, Hajer Elkout, Derek Stewart |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9e17540dac0c4dc79f696929a27686f9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Waleed H. Mahallawi, et al.
Publicado: (2021) -
Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen
por: Ava Soltani Hekmat, et al.
Publicado: (2021) -
New Tendencies in the Development of the EU Competition Law – the AstraZeneca case
por: K. V. Entin
Publicado: (2011) -
Herpes‐like skin lesion after AstraZeneca vaccination for COVID‐19: A case report
por: Mohammadreza Ardalan, et al.
Publicado: (2021) -
Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 in Southeast Bangladesh
por: Eaftekhar Ahmed Rana, et al.
Publicado: (2021)